---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123281"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:47:32.707224+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q3 net loss narrows to $10.6M on $11M collaboration revenue; cash runway into early 2026

## Summary
- Q3 net loss $10.6M vs $33.3M in Q3 2023; R&D expenses fell to $16.4M from $28.4M.
- Cash and equivalents $56.5M at Sept 30, 2024, down from $111.5M at Dec 31, 2023.
- Ozuriftamab vedotin (CAB-ROR2-ADC) shows median OS ~9 months in heavily pretreated SCCHN; FDA supported pivotal trial design.
- Evalstotug (CAB-CTLA-4) + PD-1 produced tumor reduction in all 8 first-line melanoma patients, with 1 CR and 3 PRs.
- Worldwide license agreement for CAB-Nectin-4 TCE with Context Therapeutics for up to $133.5M.

## SEC filing metadata
- accession: 0000950170-24-123281
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017024123281/0000950170-24-123281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017024123281/bcab-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123281
- JSON: https://secwatch.observer/filing/0000950170-24-123281.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.